An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or vaccine antigen
The threat to global health caused by three highly pathogenic human coronaviruses (HCoV), SARS-CoV-2, MERS-CoV and SARS-CoV, calls for the development of pan-HCoV therapeutics and vaccines. This study reports the design and engineering of a recombinant protein designated HR1LS. It contains three lin...
Saved in:
| Main Authors: | Xinling Wang, Lujia Sun, Zezhong Liu, Lixiao Xing, Yun Zhu, Wei Xu, Shuai Xia, Lu Lu, Shibo Jiang |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2023-12-01
|
| Series: | Emerging Microbes and Infections |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/22221751.2023.2244084 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Entry Inhibitors of SARS-CoV-2 Targeting the Transmembrane Domain of the Spike Protein
by: Kristin V. Lyles, et al.
Published: (2025-07-01) -
A pan-beta-coronavirus vaccine bearing conserved and asymptomatic B- and T-cell epitopes protects against highly pathogenic Delta and highly transmissible Omicron SARS-CoV-2 variants
by: Hawa Vahed, et al.
Published: (2025-12-01) -
Preparation of recombinant SARS-CoV-2 nucleocapsid protein
by: A. S. Yakovleva, et al.
Published: (2025-03-01) -
Expert: coronavirus continues to adapt in the human body
by: article Editorial
Published: (2020-07-01) -
Broad-spectrum coronavirus vaccines: integrated strategies to combat viral diversity
by: Qian He, et al.
Published: (2025-12-01)